UNLABELLED: Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG but have more favorable blood clearance than intact IgG. Radiometals offer a wide range of half-lives and emissions for matching imaging and therapy requirements and provide facile labeling of chelate-antibody conjugates. However, because of their high retention and metabolism in the kidney, the use of radiometal-labeled diabodies can be problematic for both imaging and therapy. METHODS: Having previously shown that (111)In-DOTA-polyethylene glycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the kidney uptake and retention of non-PEGylated diabody and that the two have similarly high tumor uptake and retention, we synthesized a similar derivative for an anti-tumor-associated glycoprotein 72 diabody. We also reduced the molecular size of the polydispersed PEG3400 to monodispersed PEG27 and PEG12 (nominal masses of 1,321 and 617, respectively). We performed biodistributions of their DOTA conjugates radiolabeled with (125)I, (111)In, or (64)Cu in tumor-bearing athymic mice. RESULTS: The addition of PEG3400 to the diabody reduced kidney uptake to a level (approximately 10 percentage injected dose/g) comparable to that obtained with radiometal-labeled intact IgG. The PEG27 and PEG12 diabody conjugates also demonstrated low kidney uptake without reduction of tumor uptake or tumor-to-blood ratios. When radiolabeled with (64)Cu, the DOTA-PEG12 and -PEG27 diabody conjugates gave high-contrast PET images of colon cancer xenografts in athymic mice. CONCLUSION: PEGylated diabodies may be a valuable platform for delivery of radionuclides and other agents to tumors.
UNLABELLED: Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG but have more favorable blood clearance than intact IgG. Radiometals offer a wide range of half-lives and emissions for matching imaging and therapy requirements and provide facile labeling of chelate-antibody conjugates. However, because of their high retention and metabolism in the kidney, the use of radiometal-labeled diabodies can be problematic for both imaging and therapy. METHODS: Having previously shown that (111)In-DOTA-polyethylene glycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the kidney uptake and retention of non-PEGylated diabody and that the two have similarly high tumor uptake and retention, we synthesized a similar derivative for an anti-tumor-associated glycoprotein 72 diabody. We also reduced the molecular size of the polydispersed PEG3400 to monodispersed PEG27 and PEG12 (nominal masses of 1,321 and 617, respectively). We performed biodistributions of their DOTA conjugates radiolabeled with (125)I, (111)In, or (64)Cu in tumor-bearing athymic mice. RESULTS: The addition of PEG3400 to the diabody reduced kidney uptake to a level (approximately 10 percentage injected dose/g) comparable to that obtained with radiometal-labeled intact IgG. The PEG27 and PEG12 diabody conjugates also demonstrated low kidney uptake without reduction of tumor uptake or tumor-to-blood ratios. When radiolabeled with (64)Cu, the DOTA-PEG12 and -PEG27 diabody conjugates gave high-contrast PET images of colon cancer xenografts in athymic mice. CONCLUSION: PEGylated diabodies may be a valuable platform for delivery of radionuclides and other agents to tumors.
Authors: L E Williams; A M Wu; P J Yazaki; A Liu; A A Raubitschek; J E Shively; J Y Wong Journal: Cancer Biother Radiopharm Date: 2001-02 Impact factor: 3.099
Authors: P J Yazaki; A M Wu; S W Tsai; L E Williams; D N Ikler; J Y Wong; J E Shively; A A Raubitschek Journal: Bioconjug Chem Date: 2001 Mar-Apr Impact factor: 4.774
Authors: S R Leong; L DeForge; L Presta; T Gonzalez; A Fan; M Reichert; A Chuntharapai; K J Kim; D B Tumas; W P Lee; P Gribling; B Snedecor; H Chen; V Hsei; M Schoenhoff; V Hale; J Deveney; I Koumenis; Z Shahrokh; P McKay; W Galan; B Wagner; D Narindray; C Hébert; G Zapata Journal: Cytokine Date: 2001-11-07 Impact factor: 3.861
Authors: Lin Li; Shih-Wa Tsai; Anne-Line Anderson; David A Keire; Andrew A Raubitschek; John E Shively Journal: Bioconjug Chem Date: 2002 Jan-Feb Impact factor: 4.774
Authors: M Tempero; P Leichner; J Baranowska-Kortylewicz; K Harrison; S Augustine; J Schlom; J Anderson; J Wisecarver; D Colcher Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: P J Yazaki; L Shively; C Clark; C W Cheung; W Le; B Szpikowska; J E Shively; A A Raubitschek; A M Wu Journal: J Immunol Methods Date: 2001-07-01 Impact factor: 2.303
Authors: A Goel; J Baranowska-Kortylewicz; S H Hinrichs; J Wisecarver; G Pavlinkova; S Augustine; D Colcher; B J Booth; S K Batra Journal: J Nucl Med Date: 2001-10 Impact factor: 10.057
Authors: R F Meredith; A J Bueschen; M B Khazaeli; W E Plott; W E Grizzle; R H Wheeler; J Schlom; C D Russell; T Liu; A F LoBuglio Journal: J Nucl Med Date: 1994-06 Impact factor: 10.057
Authors: Haiming Ding; Michelle M Carlton; Stephen P Povoski; Keisha Milum; Krishan Kumar; Shankaran Kothandaraman; George H Hinkle; David Colcher; Rich Brody; Paul D Davis; Alex Pokora; Mitchell Phelps; Edward W Martin; Michael F Tweedle Journal: Bioconjug Chem Date: 2013-10-31 Impact factor: 4.774
Authors: Patty Wong; Lin Li; Junie Chea; Melissa K Delgado; Erasmus Poku; Barbara Szpikowska; Nicole Bowles; Megan Minnix; David Colcher; Jeffrey Y C Wong; John E Shively; Paul J Yazaki Journal: Cancer Biother Radiopharm Date: 2017-09 Impact factor: 3.099
Authors: Lei Kang; Cuicui Li; Zachary T Rosenkrans; Jonathan W Engle; Rongfu Wang; Dawei Jiang; Xiaojie Xu; Weibo Cai Journal: J Nucl Med Date: 2020-08-21 Impact factor: 10.057
Authors: Lin Li; Desiree Crow; Fabio Turatti; James R Bading; Anne-Line Anderson; Erasmus Poku; Paul J Yazaki; Jenny Carmichael; David Leong; David Wheatcroft; Michael P Wheatcroft; Andrew A Raubitschek; Peter J Hudson; David Colcher; John E Shively Journal: Bioconjug Chem Date: 2011-03-24 Impact factor: 4.774